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Abstract 
Protein tyrosine kinases form an important target for a new class of anticancer drugs, the tyrosine kinase 
inhibitors (TKIs). Recently we demonstrated that sunitinib, an inhibitor of the membrane-associated 
vascular endothelial growth factor receptor (VEGFR), is trapped in lysosomes which isolates the drug from 
its intended target. Therefore we investigated whether this also holds for other TKIs, targeted against 
different protein kinases. For this purpose we used the ProteoExtractR kit, which enables a subcellular 
extraction separating cellular proteins into four distinct fractions covering the cytosol, membranes and 
membrane organelles (including lysosomes), nuclear proteins and the cytoskeleton. Since TKIs are 98-100 % 
protein bound we used this property to study their subcellular distribution and used Caco-2 cells as a model. 
As expected after 2 hours exposure sunitinib was trapped in cytosol (58 %) and organelles (42 % including 
lysosomes). Crizotinib, an inhibitor of ALK-EML4, showed a similar distribution. However, erlotinib, an 
inhibitor of the epidermal growth factor receptor (EGFR) showed a very low cellular accumulation and was 
limited to the organelle fraction. In contrast, the other EGFR inhibitor, gefitinib was predominantly located 
in the cytosolic (39 %) and membrane fraction (44 %). Sorafenib, another VEGFR inhibitor was 
predominantly located in the organelle fraction (85 %) and cytosol (15 %) after 2 hours, while after 24 
hours distribution decreased (9.9 fold) with a slight shift. Dasatinib, an inhibitor of BCR-Abl was located 
only in the cytosol (100 %). In general localization after 24 hours was comparable, albeit several small 
changes were seen. In conclusion protein fractionation with the ProteoExtractR Subcellular Proteome 
Extraction kit demonstrated large differences in TKI levels in various cellular organelles, with a pattern in 
agreement with lysosomal accumulation of sunitinib. 
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Protein tyrosine kinases (PTKs) regulate important signaling processes specific for the cancer cell [1]. 
Because of this important role a new class of drugs, the tyrosine kinase inhibitors (TKIs) have been 
developed [2,3]. The targets for these drugs are receptors located either on or in the membrane or 
intracellularly. This holds both for tumor cells and tumor-associated endothelial cells [4]. A decreased 
uptake or increased efflux may limit the cellular drug accumulation, and the efficacy of these drugs [5]. 
Moreover, inhibition may be reversible or irreversible; especially novel third or fourth generation TKIs 
display irreversible enzyme inhibition [6]. Recently we demonstrated that sunitinib, an inhibitor of the 
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Vascular endothelial growth factor receptor (VEGFR) accumulates in lysosomes [7], while preliminary 
experiments demonstrated a similar distribution for crizotinib, an ALK-EML4 and cMET inhibitor [5]. In 
contrast, erlotinib an inhibitor of the epidermal growth factor receptor (EGFR) showed a very low cellular 
uptake limited to the membrane [8]. Therefore, we wondered whether drug accumulation or drug 
distribution would be related to their efficacy. Since TKIs are 98-100 % plasma protein bound [9,10] we also 
wondered whether this is reflected cellularly and whether this would affect the distribution and 
accumulation of a TKI. For this purpose, we used methodology, which is commonly applied in the field of 
proteomics, in which the isolation and analysis of proteins based on their cellular location is a rapidly 
expanding field. However, the different proteins that make up a cellular environment differ greatly and are 
difficult to isolate due to size, hydrophobicity and basicity. Using the differential solubility of different 
proteins in the various subcellular compartments has led to the separation of four distinct fractions, the 
cytosolic fraction, the membrane and organelle fraction, cellular nucleus, and the cytoskeleton, Since we 
used this approach to successfully characterize the cellular distribution of a lipophilic prodrug of cytarabine 
[11] we applied the same methodology to determine the cellular distribution of TKIs. Since TKIs are almost 
completely bound to proteins, a cellular fractionation of cells incubated with drug for a suitable time period 
should also provide fractionation of the accumulated TKI. Simple extraction of each fraction should then 
provide data on the distribution of the TKI within the cell. Using a previously developed analytical liquid 
chromatography – mass spectrometry method [12] the exact proportion of TKI can be determined in each 
fraction with a high degree of specificity. Using this technique, we determined the subcellular distribution 
of six TKIs (sunitinib, crizotinib, erlotinib, gefitinib, sorafenib and dasatinib) within the colon cancer cell line, 
Caco-2. These six inhibitors were chosen based on their FDA status and the extent to which they are used in 
the clinic. Each of the selected molecules is the first line treatment in their specific area and regularly used 
for clinical patients. 
Materials and methods  
Cell culture 
The Caco-2 cell line, originating from a colorectal adenocarcinoma, was cultured at 37 °C, 5 % CO2 and 
100 % humidity, in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10 % fetal bovine serum 
(FBS) and 20 mM Hepes [13]. For the fractionation Caco-2 cells were seeded in 6 ml DMEM culture medium 
with 1 % penicillin/streptomycin in 25 cm2 flasks. Cells were allowed to attach and grow for 72 hours 
(aiming at an ultimate cell number of 3-5x106 cells). Attached cells were than exposed to either 10 µM 
erlotinib, gefitinib, sorafenib, sunitinib, crizotinib or 1 µM dasatinib for 2 and 24 hours. 
Next, medium was aspirated and cells were washed three times with 10 ml ice cold PBS. To each flask 
500 µl of trypsin/EDTA was added and cells were incubated for about 5-10 minutes at 37 °C, 5 % CO2 and 
100 % humidity. When cells were detached, the cells were resuspended with 1.5 ml ice cold phosphate 
buffered saline and transferred into eppendorf tubes. After centrifugation, the supernatant was discarded 
and the pellets resuspended in 200 µl of water for fractionation. 
Cellular fractionation 
The ProteoExtract®, subcellular proteome extraction kit from Calbiochem (Cat. No. 539791), was used to 
fractionate the cell pellets. The differential solubility of proteins in the various subcellular fractions was 
used to isolate these fractions by the addition of four sequential extraction buffers. Each buffer specifically 
targets a subcellular compartment while maintaining structural integrity of the cell [13]. When correctly 
applied these fractions are distinct and can separate the different subcellular compartments with minimal 
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to no mixing. Cell suspensions were centrifuged at 100-300 g for 10 minutes at 4 °C, then the supernatant 
was removed. Next, the cell pellets were washed with 2 ml ice cold washing buffer, gently resuspended, 
incubated for 5 minutes at 4 °C and centrifuged at 100-300 g at 4 °C for 10 minutes. The supernatant was 
discarded and the washing step was repeated once more. The resulting cell pellets were used to separate 4 
distinct cellular compartments. The initial stage of the extraction releases the cytosolic proteins from the 
cell, by addition of 1 ml of ice cold extraction buffer I with 5 µl protease inhibitor cocktail (PIC) to each cell 
pellet, which were incubated for 10 minutes at 4 °C and centrifuged at 500-1000 g at 4 °C for 10 minutes. 
The supernatant was then transferred quantitatively into a clean labelled tube without disturbing the pellet 
(fraction 1, representing the cytosolic proteins) and stored at -80 °C for future analysis. Subsequently, 1 ml 
of ice cold extraction buffer II with 5 µl PIC was added to each pellet to solubilize the membrane and 
organelles fraction, incubated for 30 minutes at 4 °C and then centrifuged at 5000-6000 g at 4 °C for 10 
minutes. The supernatant was transferred quantitatively into a clean tube without disturbing the pellet 
(fraction 2 representing the membrane and organelle proteins) and stored at -80°C for future analysis. 
Next, 500 µl of ice cold extraction buffer III with 5 µl PIC and 1.5 µl benzonase nuclease was added to each 
pellet, incubated for 10 minutes at 4 °C and centrifuged at 6800 g at 4 °C for 10 minutes. The supernatant 
was transferred into a clean tube without disturbing the pellet, containing nuclear proteins (fraction 3) and 
stored at -80 °C for future analysis. The last stage was to add 500 µl of extraction buffer IV with 5 µl PIC to 
each cell pellet, obtaining the components of the cytoskeleton (fraction 4) and stored at -80 °C for future 
analysis. 
Data analysis by LC-MS/MS  
All samples of the subcellular fractionation were measured using liquid chromatography coupled to 
mass spectrometry to determine the amount of drug (TKI) present using a previously developed method for 
biological materials. Briefly, 20 µl of each supernatant fraction was transferred quantitatively into a round 
bottomed 96-well plate and 80 µl of ice cold acetonitrile added. Each plate was covered with a plastic foil 
and allowed to stand for 10 minutes. Subsequently the 96-well plate was centrifuged at 1500 g at 4 °C for 
10 minutes. Next, 50 µl of each sample was transferred to a clean conical 96-well plate and covered with a 
NUNC well plate seal. Lastly, 1 µl of each sample was injected into the LC-MS/MS under the following 
conditions. A mobile phase containing 0.578 g ammonium acetate, 375 ml MilliQ water, 125 ml methanol, 
0.1 % isopropanol and 1000 ml acetonitrile with a pH of 7.8 was used at 350 µl/min. Before use, the mobile 
phase was filtered using a nylon filter paper of 0.2 µm and subsequently degassed for 10 minutes. 
Chromatography was performed on a Phenomenex prodigy ODS 3 column (100x2 mm, 3 µm). 
Data analysis 
Concentration of compounds determined by LC-MS/MS in each of the fractions was normalized to total 
volume of the collected fraction and quantified as accumulated drug within each fraction (fmol). Protein 
content of each fraction was determined and data normalised to fmol/mg protein. The percentage of drug 
observed in each fraction was then determined in relation to the total drug accumulation (the sum total of 
all fractions per compound). Fold changes between the 2 hour and 24 hour accumulation time points were 
determined as the ratio of total drug accumulated at the 2 hour mark to the total accumulated at the 24 
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Results 
Using the proteome extraction kit we managed to separate the proteins bound into representative 
fractions of the cellular compartments, even when accumulated at very low levels. Sunitinib has previously 
been shown to accumulate within the lysosomal compartment of the cellular makeup, where it can reach 
very high concentrations. Hence, sunitinib was used as a control for the occurrence of lysosomal 
accumulation. As expected after 2 hours sunitinib was predominantly located in the cytosol (57.5 %), 
membranes and membrane organelles (42.1 %) (e.g. lysosomes). After 24 hours no distribution change was 
observed, although the absolute amount of sunitinib decreased 3.9 fold (Tables 1 and 2; Figure 1). 




Sunitinib Crizotinib Erlotinib Gefitinib Sorafenib Dasatinib 
Cytosolic Fraction (1) 
2 57.5 58.3 10.1 38.8 15.3 100 
24 56.6 41.7 0.0 56.3 0.0 55.6 
Membrane Fraction (2) 
2 42.1 41.7 7.1 44.4 84.7 0.0 
24 40.2 56.4 0.0 30.0 60.4 27.9 
Organelles Fraction (3) 
2 0.4 0.0 3.6 16.8 0.0 0.0 
24 2.7 2.0 0.0 11.0 13.9 0.0 
Cytoskeletal Fraction (4) 
2 0.0 0.0 79.2 0.0 0.0 0.0 
24 0.5 0.0 100.0 2.8 25.7 16.5 
Values are percentages (%) of total cellular accumulation after 2 and 24 hr of analyses performed in duplicate 
 
Table 2. Time dependence of total cellular accumulation of 6 TKIs 
Drug 
Total cellular accumulation (fmol/mg protein) 
2 hours 24 hours 
Sunitinib 25692.8 4218.4 
Crizotinib 5581.4 19867.6 
Erlotinib 314.9 88.4 
Gefitinib 1572.8 462.9 
Sorafenib 2056.2 267.1 
Dasatinib 244.4 97.1 
Values are means of analyses performed in duplicate. SEM was below 15 % 
Crizotinib showed a similar distribution pattern compared to sunitinib. After 2 hours it was highly 
distributed into the cytosol (58.3 %), membranes and membrane organelles (41.7 %). Although the 
distribution remained consistent after 24 hours a 4.5-fold increase in accumulation was observed.  
One TKI, which showed a totally different distribution pattern, was erlotinib (Table 1). A distribution of 
erlotinib throughout the whole cell was observed after 2 hours exposure, although most of the 
accumulated erlotinib was located in cytoskeleton components. After 24 hours total accumulation 
decreased 20-fold and was located solely in the cytoskeleton.  
Gefitinib, which also inhibits EGFR showed a completely different pattern both after 2 and 24 hours 
exposure (Table 1). After 2 hours gefitinib was located in the cytosol (38.8 %), membranes and membrane 
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organelles (44.4 %) and nuclear proteins (16.8 %), but not in the cytoskeleton as erlotinib, which hardly 
changed after 24 hours.  
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Figure 1. Pie chart of the cellular distribution of sunitinib and dasatinib after 2 and 24 hours exposure to 10 
μM of either sunitinib or dasatinib respectively 
Both sorafenib and dasatinib do not correspond with the other TKIs and each other’s distribution 
pattern (Table 1; Figure 1). After two hours exposure, sorafenib is solely distributed in the membranes, 
membrane organelles (84.7 %) and cytosol (15.3 %).  After 24 hours accumulation decreased 9.9-fold (Table 
2) and sorafenib distribution shifted to membranes and membrane organelles (60.4%), cytoskeleton 
(25.7 %) and nuclear proteins (13.9 %). 
Accumulated dasatinib was located solely in the cytosol after two hours exposure (Figure 1; Table 1). 
ADMET & DMPK 6(3) (2018) 258-266 Subcellular localization of several structurally different TKIs 
doi: 10.5599/admet.514 263 
Similar to sorafenib, the distribution of dasatinib changed completely after 24 hours. Some of the 
accumulated dasatinib shifted from the cytosol to membranes and membrane organelles (27.9 %) and 
cytoskeleton (16.5 %). There was only a small change in total accumulated drug. 
Interestingly the total accumulation of the drugs was quite different both in the amount and the time-
course (Table 2). The absolute amount of sunitinib accumulated in the cells decreased by 3.9-fold from 2 to 
24 hours which is in agreement with the decline of sunitinib accumulation in the temperature dependent 
accumulation study after 24 hours [14]. In contrast to sunitinib, crizotinib demonstrated a 4.5-fold increase 
after 24 hours. Accumulation of erlotinib was very low and even decreased after 24 hours to 5.3 % of that 
after 2 hours. Also, total sorafenib accumulation decreased considerably from 2 to 24 hours. In contrast to 
the five other TKIs, the total absolute amount of dasatinib accumulation in the cell hardly changed after 24 
hours compared to 2 hours.  
Discussion 
The data show a large difference in both the cellular uptake and distribution. Structurally the TKIs 
investigated differ significantly (Figure 2) with a SMILE correlations of less than 0.4 with a median of 
0.206538 (range 0.154453 – 0.389155) as calculated by ChemMine, Table 3 [15]. No relationship could be 
determined between the cellular localization of the molecules to their structural makeup. The nature of the 
accumulation of these compounds is highly dependent on the degree to which they are lysosomally 
accumulated, our data demonstrates that sunitinib and crizotinib are in agreement with the physical 
properties of lysosomal accumulation. For sunitinib, the lysosomal accumulation has also been 
demonstrated by using its fluorescent properties which co-localized with the Lysotracker, a marker for 
lysosomes [7]. Moreover, pre-incubation with Bafilomycin-A prevented trapping of sunitinib in the 
lysosomes [7,16]. Sunitinib achieves very high cellular concentrations since it has been shown that 90% of 
accumulated drug is held within lysosomes within the cell structure. The cell survives this accumulation 
since the bulk of the drug is isolated away from its targets. The relationship between physiochemical 
properties and the observed absorption characteristics is currently under investigation and out of the scope 
of this paper. 
 
Table 3. Comparison of molecular structures for crizotinib, dasatinib, erlotinib, gefitinib, sorafenib and sunitinib 
using ChemMine correlation of SMILEs. 
 Crizotinib Dasatinib Erlotinib Gefitinib Sorafenib Sunitinib 
Crizotinib  0.231458 0.196302 0.285714 0.156522 0.203147 
Dasatinib 0.231458  0.208279 0.296345 0.154453 0.275956 
Erlotinib 0.196302 0.208279  0.389155 0.17601 0.206538 
Gefitinib 0.285714 0.296345 0.389155  0.18059 0.262319 
Sorafenib 0.156522 0.154453 0.17601 0.18059  0.191546 
Sunitinib 0.203147 0.275956 0.206538 0.262319 0.191546  
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Figure 2. The molecular structures and know physical chemical properties for the six tyrosine kinase inhibitors 
under investigation  
 Also, for crizotinib we demonstrated that Bafilomycin prevented uptake into lysosomes (unpublished 
data). Trapping of these drugs is possibly mediated by a selective uptake of the drugs via multidrug 
resistance proteins, subsequently the drugs are protonated and cannot subsequently be effluxed anymore 
[17,18]. For erlotinib it is likely that it is transported into the membrane, binds to its target, but is effluxed 
before it can enter the cell [19]. In contrast, the other EGFR targeted drug (gefitinib) is taken up by an active 
transporter [13,20,21] and subsequently trapped in the cell. Sorafenib is not only actively being transported 
into the cell but is possibly also trapped in the cell, either as the parent drug or as a metabolite, since it is 
substrate for various Phase I and Phase II enzymes [22,23]. It seems to be effluxed efficiently from the cell.  
Lastly, dasatinib is taken up by the cell, but is not further distributed and is not effluxed efficiently either.  
However, its cytosolic localization is in line with its high efficacy since its target BCR-abl (only in chronic 
myeloid leukemia) is located in the cytosol [1]. 
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Conclusion 
Protein fractions contained considerable TKI levels that changed markedly over time. This could be 
demonstrated by using the ProteoExtractR Subcellular Proteome Extraction kit. In addition, it can be 
concluded that the distribution of the six TKIs differs a lot and also changed over time. This may be related 
to the different physio-chemical properties of the various TKIs, favouring either a lysosomal accumulation 
or a rapid efflux from the cell [10]. Nevertheless, sunitinib and crizotinib distribution show comparable 
patterns, probably due to the lysosomal accumulation. 
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